Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Transforming hypoglycemia prediction in adult type 1 diabetes: a systematic review and meta-analysis for precision care

Zhang Q., Zhou H., Zhu X., Lin R., Hu L., Zhu G.

Meta-analysis on Type 1 Diabetes, published in Open Life Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Open Life Sci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42117040
PMCID
PMC13157319
DOI
10.1515/biol-2025-1325

Abstract (original English)

Type 1 diabetes mellitus (T1DM) patients require lifelong insulin therapy; however, iatrogenic hypoglycemia remains a major clinical challenge, with high incidence in adults. This study evaluated the performance, methodological rigor, and clinical utility of hypoglycemia risk prediction models for adult T1DM patients to inform evidence-based risk management strategies. Following Cochrane framework and PRISMA guidelines, 18 studies were identified. Data extraction and bias assessment were conducted using the PROBAST tool. The mean area under the curve (AUC) across individual models was 0.85. Meta-analysis of AUC values revealed a pooled AUC of 0.88 (95 % CI: 0.88-0.89), indicating moderate-to-good predictive accuracy. Substantial heterogeneity was observed ( I 2 = 99.82 %, P < 0.001), mainly due to differences in prediction time windows, data sources, and validation strategies. Most studies (88.9 %) showed high or unclear risk of bias, and clinical applicability was limited, with only one study meeting criteria for low bias and high applicability. While existing models show moderate predictive performance, significant methodological limitations exist. Future research should focus on optimizing study design, conducting multi-center investigations, developing interpretable AI, standardizing validation protocols, and integrating these models into clinical practice to improve hypogl

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research